NASDAQ: KTTAPasithea Therapeutics Corp Stock
$0.79+0.00 (+0%)
Updated May 14, 2026
KTTA Price
$0.79
Fair Value Price
N/A
Market Cap
$19.80M
52 Week Low
$0.28
52 Week High
$2.06
P/E
-0.27x
P/B
0.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$20.43M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$15M
Beta
0.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KTTA Overview
Pasithea Therapeutics Corporation is a biotech company developing treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics was incorporated in 2020 and is headquartered in Miami Beach, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KTTA's potential to beat the market
- KTTA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KTTA
RankedUnranked of 461
RankedUnranked of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $231.05 | A | |
| $51.10 | A | |
| $15.84 | A |
Be the first to know about important KTTA news, forecast changes, insider trades & much more!
KTTA News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KTTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KTTA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KTTA is good value based on its book value relative to its share price (0.36x), compared to the US Biotechnology industry average (4.99x)
P/B vs Industry Valuation
KTTA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KTTA due diligence checks available for Premium users.
Valuation
KTTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.27x
Industry
16.62x
Market
21.6x
KTTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.36x
Industry
4.99x
KTTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KTTA's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.1M
Profit Margin
0%
KTTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$60.2M
Liabilities
$5.0M
Debt to equity
0.09
KTTA's short-term assets ($56.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTTA's short-term assets ($56.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTTA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KTTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
$0.0
Financing
$56.4M
KTTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KTTA vs Biotech Stocks
Pasithea Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.